Back to News
Market Impact: 0.2
Lucid Diagnostics Inc. Closes $15.0 million Series C Preferred Stock Offering
Source: Nasdaq
Company FundamentalsPrivate Markets & Venture
Lucid Diagnostics entered subscription agreements on October 21, 2026, to sell 15,000 newly designated Series C Convertible Preferred Stock shares to certain accredited investors at $1,000 per share, implying a $15 million purchase price. The provided article text is truncated before the aggregate proceeds or other terms are stated.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas